BVS vs V · rev $573.3M vs P/E 33, rev $40.00B
Bioventus Inc (BVS) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Bioventus Inc (BVS) is a medical devices company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported BVS revenue for 2024-12-31 was $573.3M. Net income was -$43.8M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. BVS currently screens at market cap $495.1M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
BVS currently screens at market cap $495.1M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the BVS and V stock pages for the full models.
Not investment advice.